| The successful strategic partnership between two outsourcing specialists has enabled virtual, small and medium-sized pharmaceutical companies to progress investigational medicinal products (IMPs) through to clinical trials manufacture, using a wide variety of materials characterisation, pre-formulation and formulation techniques.
Our collaboration with Penn Pharmaceutical Services in South Wales gives new and existing clients the opportunity to combine the state-of-the art analytical techniques for materials characterisation and product development offered by Pharmaterials with the larger scale, GMP compliant, formulation development, clinical manufacturing and stability monitoring functions offered by Penn.
The partnership has led to numerous exciting opportunities for the two organizations. Dr Chris Higgins, Penn’s Director of Business Development says Penn has a strong track-record in conducting formulation development projects to the required GMP standards for virtual, small and medium-sized pharmaceutical companies. Through our partnership with Pharmaterials we now add a host of specialist services for solid-form R&D and pre-formulation screening to our already comprehensive offering thereby operating a seamless process from project concept as far as contract manufacture.
Pharmaterials have been constantly developing our range of services since our inception in 2000 and the ability to scale up formulation products to GMP compliance is one of the key elements of our present and future strategies. We see the strategic partnership with Penn, alongside our own plans for further investment in specialist equipment and facilities, as a major phase of our growth plan. |
